A carregar...
A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investigation. Considering different target specificities...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3795025/ https://ncbi.nlm.nih.gov/pubmed/24130846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0077155 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|